Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes
Dariush Mokhtari, Nils Welsh
Clinical Science (2009) Vol. 118, Iss. 4, pp. 241-247
Closed Access | Times Cited: 41

Showing 26-50 of 41 citing articles:

Repression of the Notch pathway prevents liver damage in streptozotocin-induced diabetic mice
Eda Açıkgöz, Hüseyin Aktuğ, Gürkan Yiğittürk, et al.
Folia Histochemica et Cytobiologica (2017) Vol. 55, Iss. 3, pp. 140-148
Open Access | Times Cited: 9
Targeting polyamine biosynthesis to stimulate beta cell regeneration in zebrafish
Morgan A. Robertson, Leah R. Padgett, Jonathan Fine, et al.
Islets (2020) Vol. 12, Iss. 5, pp. 99-107
Open Access | Times Cited: 8
Metastatic Renal Cell Carcinoma: How to Make the Best Sequencing Decision After Withdrawal for Intolerance to a Tyrosine Kinase Inhibitor
Roberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Future Oncology (2013) Vol. 9, Iss. 6, pp. 831-843
Closed Access | Times Cited: 7
Deciphering the scalene association among type‐2 diabetes mellitus, prostate cancer, and chronic myeloid leukemia via enrichment analysis of disease‐gene network
Qiong Liu, Yingying Zhang, Pengqian Wang, et al.
Cancer Medicine (2019) Vol. 8, Iss. 5, pp. 2268-2277
Open Access | Times Cited: 7
Imatinib protects against human beta-cell death via inhibition of mitochondrial respiration and activation of AMPK
Andris Elksnis, Tomas A. Schiffer, Fredrik Palm, et al.
Clinical Science (2021) Vol. 135, Iss. 19, pp. 2243-2263
Open Access | Times Cited: 7
The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events
Meredith Cummins, Nick Pavlakis
Therapeutic Advances in Medical Oncology (2013) Vol. 5, Iss. 5, pp. 286-300
Open Access | Times Cited: 6
Imatinib prevents beta cell deathin vitrobut does not improve islet transplantation outcome
Aileen King, Lisa A. Griffiths, Shanta J. Persaud, et al.
Upsala Journal of Medical Sciences (2016) Vol. 121, Iss. 2, pp. 140-145
Open Access | Times Cited: 6
Treating patients with metastatic renal carcinoma: an escape from Phase III
Fable Zustovich, Giuseppe Lombardi, Patrizia Farina
Expert Review of Anticancer Therapy (2012) Vol. 12, Iss. 7, pp. 919-927
Closed Access | Times Cited: 6
Expression profiling pre‐diabetic mice to uncover drugs with clinical application to type 1 diabetes
Dimeng Pang, Katharine M. Irvine, Ahmed M. Mehdi, et al.
Clinical & Translational Immunology (2015) Vol. 4, Iss. 8
Open Access | Times Cited: 3
Treatment with Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, Decreases Serum Cholesterol in Patients with Lung Cancer
Yea Eun Kang, Ji Min Kim, Kyong Hye Joung, et al.
The Korean journal of obesity (2016) Vol. 25, Iss. 4, pp. 233-239
Open Access | Times Cited: 3
Diabetic Gastroparesis: An Emerging Role for Macrophages and Heme Oxygenase-1
Aida Habtezion, John Wiley
Gastroenterology (2010) Vol. 138, Iss. 7, pp. 2219-2223
Open Access | Times Cited: 3
Sorafenib decreases glycemia by impairing hepatic glucose metabolism
Jingjing Ma, Fang Sui, Yan Liu, et al.
Endocrine (2022) Vol. 78, Iss. 3, pp. 446-457
Closed Access | Times Cited: 2
Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes
Abdoreza Davoodi‐Semiromi, Clive Wasserfall, Azadeh Hassanzadeh, et al.
Immunogenetics (2012) Vol. 65, Iss. 1, pp. 83-90
Open Access | Times Cited: 1
Tyrphostins as a promising therapeutic tool in inflammation-related conditions
Petya Dimitrova, Nina Ivanovska
OA Inflammation (2013) Vol. 1, Iss. 1
Open Access | Times Cited: 1
Inhibiteurs des tyrosine kinases et diabète
Bertrand Cariou
Médecine des Maladies Métaboliques (2015) Vol. 9, Iss. 3, pp. 269-272
Closed Access
RIPK2 dictates insulin responses to tyrosine kinase inhibitors in obese mice
Brittany M. Duggan, Joseph F. Cavallari, Kevin P. Foley, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access
Previous Page - Page 2

Scroll to top